BERKELEY, Calif.--(BUSINESS WIRE)--Actamax Surgical Materials LLC, a DSM-DuPont Joint Venture focusing on the development and commercialization of resorbable, biocompatible surgical medical devices, today announced positive safety and efficacy results from the first clinical evaluation of its novel adhesion barrier device.
Adhesions are excessive scar tissue that forms between adjacent internal tissues. They are a consequence of normal wound healing and occur after 50-90% of surgeries. Today’s announcement brings the medical community one step closer to meeting what is widely accepted amongst surgeons as a long-term unmet need - significant reduction in the prevalence and severity of adhesions in order to minimize patient suffering, promote healing and reduce complications.
Help employers find you! Check out all the jobs and post your resume.
